AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31152441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 31152441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (all doses)
Number of subjects: 4000
Study 27810949 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-source condition
Number of subjects: 2087
Study 27810949 — intervention group
Group type: COMPARATOR
Intervention: Single-source condition
Number of subjects: 2087
Study 27471209 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 5107
Study 27471209 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 5107
Study 25081651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 105
Study 25081651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 μg
Number of subjects: 105
Study 25081651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 105
Study 25081651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg, 1.25 μg, 2.5 μg
Number of subjects: 105
Study 25081651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 22044726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation with an endotracheal tube
Number of subjects: 40
Study 22044726 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal intubation using an Easytube(®)
Number of subjects: 40
Study 20947881 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin sequential therapy
Number of subjects: 375
Study 20947881 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-250 sequential therapy
Number of subjects: 375
Study 20947881 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-500 sequential therapy
Number of subjects: 375
Study 19006732 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser (IntraLase FS30)
Number of subjects: 146
Study 15744778 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors
Number of subjects: 184
Study 15744778 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 184
Study 12548273 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐in‐1 nerve block with bupivacaine plus intravenous morphine
Number of subjects: 50
Study 12548273 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 50
Study 11031221 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loaded regimen of clopidogrel (300 mg the first day and 75 mg/d for the next 7 days)
Number of subjects: 20
Study 11031221 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of clopidogrel (75 mg/d for 8 days)
Number of subjects: 20
Study 8898135 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscrubbed, ungowned leg holder during preparation and draping
Number of subjects: 0
Study 8898135 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrubbed and gowned leg holder during preparation and draping
Number of subjects: 0
Study 8898135 — intervention group
Group type: EXPERIMENTAL
Intervention: General air counts during preparation and draping
Number of subjects: 0
Study 1894672 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic ultraviolet radiation of 254 nm
Number of subjects: 113
Study 1894672 — intervention group
Group type: COMPARATOR
Intervention: Ultra-clean air enclosure (Charnley‐Howorth air enclosure)
Number of subjects: 113
Study 1894672 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive clothing for all personnel
Number of subjects: 113
Study 6360597 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg, administered orally 30 min prior to the test meal.
Number of subjects: 26
Study 6360597 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide for patients with delayed gastric emptying.
Number of subjects: 26
Study 6360597 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide for patients with normal gastric emptying.
Number of subjects: 26
Study 31977907 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (twice weekly for 4 weeks at acupuncture points SP6, LR3, and CV4) plus conventional medication for 4 weeks, followed by conventional medication alone for 8 weeks.
Number of subjects: 29
Study 31977907 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion plus conventional medication.
Number of subjects: 29
Study 31977907 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication alone.
Number of subjects: 29
Study 30885027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (dexmedetomidine 1 µg/kg IV 15 minutes before anesthesia induction and bilateral transversus abdominis plane block with 0.375% ropivacaine 30 mL)
Number of subjects: 153
Study 30885027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 153
Study 27613490 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 901
Study 27613490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 27466608 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maize delivering 600 μg retinol equivalents (REs)/d as carotenoid plus placebo (OM)
Number of subjects: 149
Study 27466608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐carotenoid white maize plus 600 μg REs/d as retinyl palmitate (VA)
Number of subjects: 149
Study 27466608 — intervention group
Group type: COMPARATOR
Intervention: White maize plus placebo (WM)
Number of subjects: 149
Study 25267740 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, dexamethasone, and cisplatin (GDP)
Number of subjects: 619
Study 25267740 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone, cytarabine, and cisplatin (DHAP)
Number of subjects: 619
Study 22710881 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30
Study 22710881 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 30
Study 21036759 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/fluorouracil/leucovorin (IRI/FU/LV)
Number of subjects: 417
Study 21036759 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan/fluorouracil/leucovorin followed by oxaliplatin/fluorouracil/leucovorin (IRI/FU/LV followed by OXA/FU/LV)
Number of subjects: 417
Study 19159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex quantitative fluorescent PCR (QF‐PCR)
Number of subjects: 4
Study 19159546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 4
Study 19159546 — intervention group
Group type: COMPARATOR
Intervention: Ordinary PCR
Number of subjects: 4
Study 16036165 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica montana C6 and Bellis perennis C6
Number of subjects: 40
Study 16036165 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica montana C30 and Bellis perennis C30
Number of subjects: 40
Study 16036165 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 40
Study 12072066 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% methylprednisolone
Number of subjects: 0
Study 12072066 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.5% dexpanthenol
Number of subjects: 0
Study 12072066 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Number of subjects: 0
Study 12072066 — intervention group
Group type: COMPARATOR
Intervention: Dexpanthenol-containing emollient
Number of subjects: 0
Study 10500778 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg/day)
Number of subjects: 131
Study 10500778 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 131
Study 8397459 — intervention group
Group type: EXPERIMENTAL
Intervention: buflomedil
Number of subjects: 12
Study 8397459 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3529538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (25 mg/kg/day for 24 hours in four equally divided doses)
Number of subjects: 48
Study 3529538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, 25 mg/kg/day for 24 hours in four equally divided doses)
Number of subjects: 48
Study 31725697 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable Acuvue 2 (A2)
Number of subjects: 20
Study 31725697 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable Acuvue Oasys (AO)
Number of subjects: 20
Study 31725697 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable Acuvue Oasys (AODD)
Number of subjects: 20
Study 29149755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg) plus propofol (0.5mg/kg)
Number of subjects: 77
Study 29149755 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1mg/kg)
Number of subjects: 77
Study 29149755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine plus propofol
Number of subjects: 77
Study 25828946 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision coaxial cataract surgery
Number of subjects: 84
Study 25828946 — intervention group
Group type: COMPARATOR
Intervention: Small incision coaxial cataract surgery
Number of subjects: 84
Study 26056749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based prevention program
Number of subjects: 408
Study 26056749 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 408
Study 23778412 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily
Number of subjects: 68
Study 23778412 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic patients)
Number of subjects: 68
Study 21337950 — intervention group
Group type: EXPERIMENTAL
Intervention: LouseBuster treatment by experienced operators
Number of subjects: 56
Study 21337950 — intervention group
Group type: EXPERIMENTAL
Intervention: LouseBuster treatment by novice operators
Number of subjects: 56
Study 19737424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education and coaching (TEC)
Number of subjects: 265
Study 19737424 — intervention group
Group type: COMPARATOR
Intervention: Educationally-enhanced usual care (EUC)
Number of subjects: 265
Study 17013356 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (stainless steel needle inserted to a depth of 20 mm, manually stimulated for 20 seconds)
Number of subjects: 31
Study 17013356 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (guide tube without a needle tapped on the skin)
Number of subjects: 31
Study 12873325 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSPAN therapy
Number of subjects: 56
Study 12873325 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study 11134127 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 26
Study 11134127 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 26
Study 11134127 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control for type 1)
Number of subjects: 26
Study 11134127 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control for type 2)
Number of subjects: 26
Study 9533167 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy administered once every one or two weeks or several-times-daily
Number of subjects: 0
Study 9533167 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant therapy (general)
Number of subjects: 0
Study 7999650 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural alfentanil 500 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of alfentanil 20 micrograms/mL in 0.125% bupivacaine
Number of subjects: 24
Study 7999650 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 50 micrograms in 10 mL 0.125% bupivacaine, followed by continuous infusion of fentanyl 2 micrograms/mL in 0.125% bupivacaine
Number of subjects: 24
Study 3177951 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 30
Study 30278457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100F/HMPnano
Number of subjects: 12
Study 30278457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100F/HMP
Number of subjects: 12
Study 30278457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29231338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at zygapophyseal joint, transverse process, superior gluteus nerve into the hip point, and Weizhong (BL 40)
Number of subjects: 80
Study 29231338 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture at Qihaishu (BL 24), Jiaji (EX-B 2) of L2-L4, superior gluteus nerve into the hip point, and Weizhong (BL 40)
Number of subjects: 80
Study 25882438 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) - 3 injections of 1 mL
Number of subjects: 50
Study 25882438 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) - 3 injections of 1 mL
Number of subjects: 50
Study 23127590 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS+
Number of subjects: 188
Study 23127590 — intervention group
Group type: COMPARATOR
Intervention: PGS‐
Number of subjects: 188
Study 23127590 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 188
Study 20705281 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian-tapping (MT)
Number of subjects: 70
Study 20705281 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 70
Study 18512510 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2 (TE3) + resin cement post (rcp) + Duo‐link (Dl)
Number of subjects: 30
Study 18512510 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step Plus (TE2) + rcp + Dl
Number of subjects: 30
Study 18512510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian/One‐Step Plus (SE) + rcp + Dl
Number of subjects: 30
Study 16497625 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy with 1.5% acetic acid (A1 evaluation)
Number of subjects: 60
Study 16497625 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification endoscopy with 1.5% acetic acid (A2 evaluation)
Number of subjects: 60
Study 16497625 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by inexperienced investigators
Number of subjects: 60
Study 16497625 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by experienced investigators
Number of subjects: 60
Study 16497625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 60
Study 14605329 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA treatment
Number of subjects: 61
Study 10919021 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy with ligation (EISL)
Number of subjects: 24
Study 10919021 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 24
Study 8881885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy extracorporal shock wave therapy (3000 impulses of 0.08 mJ/mm2)
Number of subjects: 50
Study 8881885 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 impulses of 0.08 mJ/mm2)
Number of subjects: 50
Study 8267195 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with patient‐controlled intravenous morphine (GA)
Number of subjects: 60
Study 8267195 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia combined with epidural fentanyl analgesia (RA)
Number of subjects: 60
Study 8267195 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 60
Study 8267195 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (RA)
Number of subjects: 60
Study 3710294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (60 mg daily)
Number of subjects: 270
Study 3710294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 29985456 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 12
Study 29985456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27940686 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based early preventative care program with 9 home visits focusing on infant development, parental mental health, and parent-infant relationship.
Number of subjects: 120
Study 27940686 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based early preventative care program
Number of subjects: 120
Study 27940686 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 25300221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including implementation support, staff training, resources, recognition and incentives, consensus and leadership strategies, follow-up support and implementation feedback.
Number of subjects: 70
Study 25300221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention support).
Number of subjects: 70
Study 22068670 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate (PMEA)‐coated circuits + leukocyte filters (n = 214)
Number of subjects: 875
Study 22068670 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated ECC + full Hammersmith aprotinin (n = 212)
Number of subjects: 875
Study 22068670 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA‐coated ECC + leukofilters + full Hammersmith aprotinin (n = 199)
Number of subjects: 875
Study 22068670 — intervention group
Group type: COMPARATOR
Intervention: Control - no treatment (n = 250)
Number of subjects: 875
Study 20204892 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceptor specialty (assigned randomly or by student recruitment/specialty request)
Number of subjects: 0
Study 20204892 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceptor experience (time spent in ambulatory clinics and direct patient interaction)
Number of subjects: 0
Study 17823507 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak extract rinse
Number of subjects: 0
Study 17823507 — intervention group
Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 0
Study 17564408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 9 g nightly
Number of subjects: 228
Study 17564408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g and 9 g nightly
Number of subjects: 228
Study 17564408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (all doses)
Number of subjects: 228
Study 12244893 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroplant (enteric coated capsules containing 90 mg peppermint oil and 50 mg caraway oil each)
Number of subjects: 16
Study 12244893 — intervention group
Group type: COMPARATOR
Intervention: Immediate release formulation (5 capsules containing 36 mg peppermint oil and 20 mg caraway oil each)
Number of subjects: 16
Study 12244893 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteroplant (enteric coated capsules)
Number of subjects: 16
Study 12244893 — intervention group
Group type: COMPARATOR
Intervention: Immediate release formulation
Number of subjects: 16
Study 9889031 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 every 28 days for five cycles
Number of subjects: 81
Study 9889031 — intervention group
Group type: COMPARATOR
Intervention: Epidoxorubicin 120 mg/m2 iv plus paclitaxel 150 mg/m2 iv every 28 days
Number of subjects: 81
Study 7484887 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4‐8 mg orally) with possible addition of isradipine (5‐10 mg orally) and hydralazine if necessary
Number of subjects: 25
Study 7484887 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched normotensives)
Number of subjects: 25
Study 1791799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (intravenous infusion)
Number of subjects: 30
Study 1791799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokio‐Akita (TA) surfactant (endotracheal administration)
Number of subjects: 30
Study 1791799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (endotracheal administration)
Number of subjects: 30
Study 532708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography and plethysmography
Number of subjects: 55
Study 532708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 55
Study 532708 — intervention group
Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 55
Study 31756675 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 19
Study 31756675 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 19
Study 31398441 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12
Study 31398441 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 12
Study 31398441 — intervention group
Group type: COMPARATOR
Intervention: 0 mg caffeine (placebo)
Number of subjects: 12
Study 31398441 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD
Number of subjects: 12
Study 28433216 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD‐XI ≤16
Number of subjects: 453
Study 28433216 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD‐Na ≤17
Number of subjects: 453
Study 28433216 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD‐XI and MELD‐Na
Number of subjects: 453
Study 26372318 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction in home heating
Number of subjects: 359
Study 24064163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleached only (Group 2)
Number of subjects: 20
Study 24064163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etched for 15 seconds prior to bleaching (Group 3)
Number of subjects: 20
Study 24064163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etched for 30 seconds prior to bleaching (Group 4)
Number of subjects: 20
Study 24064163 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1) - unbleached and had no previous acid etching
Number of subjects: 20
Study 20678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser welding with joint opening of 0·6 mm
Number of subjects: 60
Study 20678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser welding with joint opening of 0·0 mm and 3·5 mm diameter
Number of subjects: 60
Study 20678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of porosity
Number of subjects: 60